Recent developments in melatonin receptor ligands

Bibliography

• REITER RJ: Pineal melatonin: cell biology of its synthesis and its physiological interactions. Endocrinol. Rev. (1991) 12:151-180. An interesting review on the physiological properties ofmelatonin and its role in the circadian rhythm.
   Google Scholar
• KLEIN DC, ROSEBOOM PH, COON SL: New light is shin- ing on the melatonin rhythm enzyme. Trends Endocri-nol. Metab. (1996) 7:106-112. An up-to-date review on the key enzyme in the synthesis ofmelatonin: serotonin-N-acetyltransferase (5-HT-NAT).
   Google Scholar
• MOORE RY: Neural control of the pineal gland. Behav. Brain Res. (1996) 73:125–130.
   PubMed Web of Science ®Google Scholar
• ALONSO-GOMEZ AL, IUVONE PM: Melatonin biosynthe-sis in cultured chick retinal photoreceptors: calcium and cyclic AMP protect N-acetyltransferase from inacti-vation in cycloheximide-treated cells. J. Neurochem. (1995) 65:1054–1060.
   PubMedGoogle Scholar
• REPPERT SM, WEAVER DR, GODSON C: Melatonin recep-tors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. (1996) 17:100-102. A review on the localisation of melatonin in the gastrointesti-nal system.
   Google Scholar
• REPPERT SM, WEAVER DR, EBISAWA T: Cloning and char- acterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neu-ron (1994) 13:1177-1185. The presentation of the cloned melatonin receptors.
   Google Scholar
• REPPERT SM, GODSON C, MAHLE CD et al: Molecular characterization of a second melatonin receptor ex-pressed in human retina and brain: the Meth, mela-tonin receptor. Proc. NatL Acad. Sci. USA (1995) 92:8734-8738. The cloning and expression in COS-1 cells of the humanMelib receptor and its preliminary pharmacological proper-ties.
   Google Scholar
• EBISAWA T, KARNE S, LERNER M, REPPERT SM: Expres- sion cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc. Natl. Acad. Sci. USA (1994) 91:6133-6137. The paper reported the first melatonin receptor characterisedand demonstrated its coupling to G-proteins for the inhibi-tion of cAMP synthesis.
   Google Scholar
• QUAY WB, BAGNARA JT: Relative potencies of indolic and related compounds in the body-lightening reac-tion of larval Xenopus. Arch. Int. Pharmacodyn. (1964) 150:137–143.
   PubMedGoogle Scholar
• LIU F, YUAN H, SUGAMORI KS et al.: Molecular and func-tional characterization of a partial cDNA encoding a novel chicken brain melatonin receptor. FEBS Lett. (1995) 374:273–278.
   PubMed Web of Science ®Google Scholar
• GODSON C, REPPERT SM: The Melia melatonin receptoris coupled to parallel signal transduction pathways. En-docrinology (1997) 138:397–404.
   PubMed Web of Science ®Google Scholar
• DUNCAN MJ, TAKAHASHI JS, DUBOCOVICH ML: Charac-teristics and autoradiographic localization of 24125114-odomelatonin binding sites in Djungarian hamster brain. Endocrinology (1989) 125:1011-1018. The phosphatidylinositol phosphate hydrolysis is an addi-tional pathway of the melatonin signal.
   Google Scholar
• STANKOV B, FRASCHINI F, REITER RJ: Melatonin bindingsites in the central nervous system. Brain. Res. Rev. (1991) 16:245–256.
   PubMedGoogle Scholar
• EVANS BK, MASON R, WILSON VG: Evidence for directvasoconstrictor activity of melatonin in 'pressurized' segments of isolated caudal artery from juvenile rats. Naunyn-Schmiedeberg's Arch. Pharmacol. (1992) 346:362–365.
   Google Scholar
• SONG Y, TAM PC, POON AMS, BROWN GM, PANG SF:2412511Iodomelatonin-binding sites in the human kid-ney and the effect of guanosine 5'4)-(3-thiotriphosphate). J. Clin. Endocrinol. Metab. (1995) 80:1560–1565.
   PubMed Web of Science ®Google Scholar
• LOPEZ-GONZALES MA, MARTIN-CACAO A, CALVO JR et al.:Specific binding of 241251Rodomelatonin by partially purified membranes of rat thymus. J. Neuroimmunol. (1993) 45:121–126.
   PubMed Web of Science ®Google Scholar
• RAFII-ELD-IDRISSI M, CALVO JR, POZO D, HARMOUCH A,GUERRERO JM: Specific binding of 241251liodomela-tonin by rat splenocytes: characterization and its role on regulation of cyclic AMP production. J. Neuroimmu-nol. (1995) 57:171-178. The presence of the melatonin receptors in the thymus.
   Google Scholar
• REITER RJ, OH C-S, FUJIMORI 0: Melatonin: its intracellu-lar and genomic actions. Trends Endocrinol. Metab. (1996) 7:22–27.
   PubMedGoogle Scholar
• ARENDT J, DEACON S, ENGLISH J, HAMPTON S, MORGAN L: Melatonin and adjustment to phase shift. J. Sleep Res. (1995) 4:74–79.
   PubMed Web of Science ®Google Scholar
• ARENDT J, DEACON S: Treatment of circadian rhythm disorders - melatonin. Chronobiol. Int. (1997) 14:185–204.
   PubMed Web of Science ®Google Scholar
• WIRZ-JUSTICE A, AMSTRONG SM: Melatonin: nature's soporific. J. Sleep Res. (1996) 5:137–141.
   PubMed Web of Science ®Google Scholar
• BLEHAR MC, LEWY AJ: Seasonal mood disorders: con-sensus and controversy. Psychopharmacol. Bull. (1990) 4:465–482.
   Google Scholar
• REITER RJ: The pineal and its hormone in the control ofreproduction in mammals. Endocrinol. Rev. (1980) 1:109–131.
   PubMedGoogle Scholar
• YING S-W, NILES LP, CROCKER C: Human malignant melanoma cells express high-affinity receptors for melatonin: anti-proliferative effects of melatonin and 6-chloromelatonin. Eur. j Pharmacol. - Mol. Pharmacol Section (1993) 246:89–96.
   PubMedGoogle Scholar
• BLASK DE, WILSON ST, ZALATAN F: Physiological mela-tonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Research (1997) 57:1909-1914. The oncostatic activity of melatonin on the human breast tu-mour cell line MCF-7 is described and the antiproliferative ef-fect is mediated through glutathione.
   Google Scholar
• LISSONI P, BRIVIO 0, BRIVIO F et al.: Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J. Pin-eal Res. (1996) 21:239–242.
   Google Scholar
• REITER RJ: Oxygen radical detoxification processes dur-ing ageing: the functional importance of melatonin. Ageing Clin. Exp. Res. (1995) 7:340-351. The article presents the anti-oxidant properties of melatoninand its putative anti-ageing role.
   Google Scholar
• MAHLE CD, TAKAKI KS, WATSON AJ: Melatonin receptor ligands and their potential clinical applications. In: An-nual Reports in Medicinal Chemistry Bristol JA (Ed.), Aca-demic Press, London (1997) 32:31–40.
   Google Scholar
• RICHARDSON BA, VAUGHAN MK, PETTERBORG LJ et al.: Natural and synthetic analogues of melatonin and re-lated compounds. I. Effects on the reproductive system of the male Syrian hamster. J. Neural Transm. (1983) 56:187-197. A review of the recent melatonin receptor ligands (SAR) and of their potential clinical applications.
   Google Scholar
• KENNAWAY DJ, HUGEL HM, ROWE SA: Characterization of the chicken brain melatonin-binding protein using iodinated and tritiated ligands. J. Pineal Res. (1994) 17:137–148.
   PubMedGoogle Scholar
• MORGAN PJ, WILLIAMS LM, DAVIDSON G, LAXSON W, HOWELL E: Melatonin receptors of the ovine pars tuber-alis: characterization and autoradiographical localiza-tion. J. Neuroendocrinol. (1989) 1:1–4.
   PubMedGoogle Scholar
• MORGAN PJ, BARRETT P, HAZLERIGG D et al.: Melatonin receptors couple through a cholera toxin-sensitive mechanism to inhibit cyclic AMP in the ovine pituitary. Neuroendocrinol (1995) 7:361-369. The demonstration of the presence of melatonin receptors by autoradiography in the ovine pars tuberalis.
   Google Scholar
• MASON R, BROOKS A: The electrophysiological effects of melatonin and a putative melatonin antagonist (N-acetyl-tryptamine) on rat suprachiasmatic neurones in vitro. Neurosci. Lett. (1988) 95:296-301. The inhibition of cyclic AMP synthesis by melatonin in the pi-tuitary.
   Google Scholar
• MASON R, DELAGRANGE P, GUARDIOLA B: Melatonin and S20098 mediated resetting of rat suprachiasmatic circadian clock neurones in vitro. Br. J. Pharmacol (1993) 108:32P.
   Google Scholar
• KIRK KL: Synthesis of ring-fluorinated serotonins andmelatonins. J. Heterocyclic Chem. (1976) 13:1253-1256. The influence of S20098, a melatonergic agonist, on the phase-shift of the suprachiasmatic nucleus.
   Google Scholar
• ABRAMOVITCH RA, SHAPIRO D: Tryptamines, carbo-lines and related compounds: Part II. A convenient syn-thesis of tryptamines and B-carbolines. J. Chem. Soc. (1956) 4589–4592.
   Google Scholar
• CLEMENS JA, FLAUGH ME: Development of drugs to modify the actions of melatonin. J. Neural Transm. (1986) 21:451–459.
   Google Scholar
• CLEMENS JA, FLAUGH ME, PARLI J, SAWYER BD: Inhibi-tion of luteinizing hormone release and ovulation by 6-chloro and 6-fluoromelatonin. Neuroendocrinology (1980) 30:83–87.
   PubMedGoogle Scholar
• ZAWILSKA JB, NOWAK JZ: Regulatory mechanism in melatonin biosynthesis in retina. Neurochem. mt. (1992) 20:23–36.
   PubMed Web of Science ®Google Scholar
• ROLLAG MD: Response of amphibian melanophores tomelatonin. Pineal Res. Rev. (1988) 6:67–93.
   Google Scholar
• SUGDEN D: Aggregation of pigment granules in singlecultured Xenopus laevis melanophores by melatonin analogues. Br. J. Pharmacol (1991) 104:922–927.
   PubMedGoogle Scholar
• LISSONI P, BARNI S, TANCINI G et al.: Immunoendocrinetherapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology (1995) 52:163-166. The effects of melatonin analogues on the melanin aggrega-tion in the cultured melanophores: a functional test.
   Google Scholar
• DAS UN: Melatonin in the pathobiology and treatment of cancer. Cancel 1. (1995) 8:103–108.
   Google Scholar
• DUBOCOVICH ML, TAKAHASHI JS: Use of 241251Bodo-melatonin to characterize melatonin binding sites in chicken retina. Proc. Natl. Acad. Sci. USA (1987) 84:3916-3920. The paper presented the use of 24125Iliodomelatonin as aradioligand for the characterisation of melatonin receptors. It was an essential step in the understanding of the role of mela-tonin.
   Google Scholar
• VAKKURI 0, LEPPALUOTO J, VUOLTEENAHO 0: Develop-ment and validation of a melatonin radioimmunoassay using radioiodinated melatonin as a tracer. Acta Endo-crinol. (1984) 106:152–157.
   PubMedGoogle Scholar
• DURANTI E, STANKOV B, SPADONI G et al.: 2 -Bromomelatonin: synthesis and characterization of a potent melatonin agonist. Life Sci. (1992) 51:479–485.
   PubMedGoogle Scholar
• HIRATA F, HAYAISHI 0, TOKUYAMA T, SENOH S: In vitroand in vivo formation of two new metabolites of mela-tonin. J. Biol. Chem. (1974) 249:1311–1314.
   PubMed Web of Science ®Google Scholar
• SPADONI G, STANKOV B, DURANTI A et al.: 2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding af-finity for the melatonin receptor, and evaluation of the biological activity. J. Med. Chem. (1993) 36:4069-4074. The authors pointed out the role of 2-substitution on the in-dole ring to increase the affinities of the molecules for mela-tonin receptors and emphasised an interesting structure-activity relationship for the indolic melatonin ana-logues.
   Google Scholar
• GARRATT PJ, JONES R, TOCHER DA, SUGDEN D: Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. J. Med. Chem. (1995) 38:1132–1139.
   Google Scholar
• TARZIA G, DIAMANTANI G, DI GIACOMO B et al.: 142-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues. J. Med. Chem. (1997) 40:2003–2010.
   Google Scholar
• HEWARD CB, HADLEY ME: Structure-activity relation-ships of melatonin and related indoleamines. Life Sci. (1975) 17:1167-1178. The introduction of the ethylamido chain on the nitrogen atom of the indole ring gave a melatonin isomer, a potent melatonin receptor agonist.
   Google Scholar
• SUGDEN D: Effect of putative melatonin receptor an-tagonists on melatonin-induced pigment aggregation in isolated Xenopus laevis melanophores. Eur. J. Phar-macol. (1992) 213:405–408.
   PubMed Web of Science ®Google Scholar
• DUBOCOVICH ML: Luzindole (N-0774): a novel mela-tonin receptor antagonist. J. Pharmacol. Exp. Ther. (1988) 246:902–910.
   PubMed Web of Science ®Google Scholar
• HOWELL HE, MORGAN PJ: Luzindole (2-benzyl-N- a c e ty lt ry pt a min e), 5-methoxytryptamine, N-acetyltryptamine and 6-methoxy-2-benzoxazolinone activity in ovine pars tuberalis cells. Adv. Pineal Res. (1991) 205–207.
   Google Scholar
• ZISAPEL N, LAUDON M: A novel melatonin antagonist af-fects melatonin-mediated processes in vitro and in vivo. Eur. J. Pharmacol. (1987) 136:259–260.
   PubMedGoogle Scholar
• MOLINARI EJ, NORTH PC, DUBOCOVICH ML: 241251liodo-5-methoxycarbonylamino-N-acetyltryptamine: a selec-tive radioligand for the characterization of melatonin ML2 binding sites. Eur. J. Pharmacol. (1996) 301:159–168.
   PubMed Web of Science ®Google Scholar
• FROHN MA, SEABORN CJ, JOHNSON DW et al.: Structure-activity relationship of melatonin analogues. Life Sci. (1980) 27:2043-2046. The determination of the binding parameters of the first ligand selective for the ML2 site.
   Google Scholar
• GARRATT PJ, JONES R, ROWE SJ, SUGDEN D: Mapping the melatonin receptor. 1. The 5-methoxy group of mela-tonin is not an essential requirement for biological ac-tivity. BioMed. Chem. Lett. (1994) 4:1555–1558.
   Google Scholar
• TADA M, IWATA R, SUGIYAMA H et al.: A rapid synthesis of [fluoroacetyl-1 8F]fluoromelatonin (N-[1 8F] fluoroacety1-5-methoxytryptamine) a potential diag-nostic imaging agent. J. Labelled Compounds Radiopharm. (1993) 33:601–606.
   Google Scholar
• ANTS Y, ZISAPEL N: Affinity labeling of melatonin bind-ing sites in the hamster brain. Biochem. Biophys. Res. Commun. (1991) 178:1147–1152.
   PubMedGoogle Scholar
• CHONG NWS, EVANS JE, SUGDEN D: N-Bromoacety1-5-methoxytryptamine: an irreversible melatonin ligand? Biochem. Biophys. Res. Commun. (1993) 193:1355–1361.
   PubMedGoogle Scholar
• CHAPMAN NB, CLARKE K, HUMPHRIES AJ, SARAF SUD:Pharmacologically active benzo[b]thiophen deriva-tives. Part VII. Analogues of tryptamine and hetero-auxin. J. Chem. Soc. (1969) 1612–1616.
   Google Scholar
• COMPAIGNE E, NEISS ES, PFEIFFER CC, BECKR A:Benzo[b]thiophen derivatives. XII. Synthesis of some 3-benzo[b]thienylalkylamines and comparison of their central nervous system activity with tryptamine isosteres. J. Med. Chem. (1968) 11:1049–1054.
   Google Scholar
• COMPAIGNE E, DINNER A: Benzo[b]thiophene deriva-tives XVI. The sulfur isosteres of melatonin, bufo-tenine, 5-hydroxytryptophan and related structures. J. Med. Chem. (1970) 13:1205–1208.
   Google Scholar
• COMPAIGNE E, HOMFELD E, MATS DF: Benzo[b]thio-phene derivatives XXIII. Derivatives of 5,6-dihydroxy-3-benzo[b]thienylacetic acid. J. Heterocyclic Chem. (1978) 1351–1359.
   Google Scholar
• COMPAIGNE E, SMITH HA, SANDHU JS, KIM CS: Benzo[b]thiophene derivatives XXVI. 5-Methoxy-6-chloro-3-13 acetamidoethylbenzo[b]thiophene, a blocked analog of melatonin. J. Heterocyclic Chem. (1983) 20:55–59.
   Google Scholar
• RUFFIN N, REED B, FINNIN B: The specificity of mela-tonin as a melanophore controlling factor in the pencil fish. Life Sci. (1969) 8:1167–1174.
   PubMedGoogle Scholar
• HALLMAN G, HAGELE K: Tryptamin, serotonin und melatonin analoga. Annalen (1963) 147–149.
   Google Scholar
• LAITEM L, THIBAUT P, CHRISTIAENS L: Synthèse de l'ana-logue sélénié de la mélatonine. J. Heterocyclic Chem. (1976) 13:469–473.
   Google Scholar
• MENTZER C, BEAUDET C: Sur un analogue naphta16-nique de la sérotonine. C. R. Acad. Sci. Paris (1952) 234:1692-1694. The first paper that described the bioisosteric properties ofindole and naphthalene rings for the preparation of serotonin analogues.
   Google Scholar
• ANDRIEUX J, ANKER D, MENTZER C: Synthèse de nou-veaux analogues naphtaléniques de la sérotonine. Chimie Thérapeutique - Eur. J. Med. Chem. (1966) 57–61.
   Google Scholar
• YOUS S, ANDRIEUX J, HOWELL HE et al.: Novel naphtha-lenic ligands with high affinity for the melatonin recep-tor. J. Med. Chem. (1992) 35:1484-1486. The authors presented the first naphthalenic analogues ofmelatonin and described several compounds that are several orders of magnitude more potent than melatonin in binding assays.
   Google Scholar
• DEPREUX P, LESIEUR D, MANSOUR HA et al.: Synthesisand structure-activity relationships of novel naphtha-lenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J. Med. Chem. (1994) 37:3231–3239.
   PubMed Web of Science ®Google Scholar
• LANGLOIS M, BREMONT B, SHEN S et al.: Design and syn-thesis of new naphthalenic derivatives as ligands for 2[12511-iodomelatonin binding sites. J. Med. Chem. (1995) 38:2050–2060.
   PubMedGoogle Scholar
• GUARDIOLA-LEMAITRE B, DELAGRANGE P: Melatonin analogues. From pharmacology to clinical application. Proceedings of the XIIIth International Symposium of Medici-nal Chemistry Muller JC (Ed.), (1995) S30:643s–651s.
   Google Scholar
• YING SW, RUSAK B, DELAGRANGE P et al: Melatonin ana-logues as agonists and antagonists in the circadian sys-tem and other brain areas. Eur. J. Pharmacol. (1996) 296:33–42.
   PubMed Web of Science ®Google Scholar
• GARRATT PJ, TRAVARD S, VONHOFF S: Mapping the melatonin receptor. 4. Comparison of the binding af-finities of a series of substituted phenylalkyl amides. J. Med. Chem. (1996) 39:1797–1805.
   Google Scholar
• COPINGA S, TEPPER PG, GROL CJ, HORN AS, DUBOCO-VICH ML: 2-Amido-8-methoxytetralins: a series of non-indolic melatonin-like agents. J. Med. Chem. (1993) 36:2891-2898. The use of the structural analogy between serotoninergicligands and melatonin to design an interesting constrained melatonergic ligand.
   Google Scholar
• COPINGA S, VAN BRUNAMELEN G, DRIFHOUT WJ et al.:Synthesis and pharmacological evaluation of 4-ary1-2-amidotetralins, nonindolic melatonin receptor agents. XIIIth International Symposium of Medicinal Chemistry. Paris (September, 1994) 164.
   Google Scholar
• DUBOCOVITCH ML, MASANA STANCA IACOB MI, SAURI DM: Melatonin receptor antagonists that differentiate between the human Melia and Mehl, recombinant sub-types are used to assess the pharmacological profile of the rabbit retina ML 1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. (1997) 355:365-375. The first paper that reported compounds with good selectiv-ity for the Melib receptor vs. the Melia receptor
   Google Scholar
• DUBOCOVICH ML: Characterization of a retinal mela-tonin receptor. J. Pharmacol. Exp. Ther. (1995) 234:395–401.
   Google Scholar
• GARRATT PJ, VONHOFF S, ROWE SJ, SUGDEN D: Mapping the melatonin receptor. 2. Synthesis and biological ac-tivity of indole-derived melatonin analogues with re-stricted conformations of the C-3 amidoethane side chain. BioMed. Chem. Lett. (1994) 4:1559–1564.
   Google Scholar
• SPADONI G, BALSAMINI C, DIAMANTANI G et al.: Confor-mationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity and molecular modeling study. J. Merl. Chem. (1997) 40:1990-2002. The article presents various cyclic indolic derivatives pos-sessing a wide affinity range for quail melatonin receptors. The authors emphasised the importance of the position of the ethylamido chain for recognition by the receptors and presented an interesting pharmacophore model.
   Google Scholar
• SUGDEN D, DAVIES DJ, GARRATT PJ, JONES R, VONHOFF S: Radioligand binding affinity and biological activity of the enantiomers of a chiral melatonin analogue. Eur. J. Pharmacol. (1995) 287:239-243. The description of the enantioselectivity of the melatonin re-ceptor for a tricyclic indole derivative.
   Google Scholar
• PICKERING H, SWORD S, VONHOFF S, JONES R, SUGDEN D: Analogues of diverse structures are unable to differ-entiate native melatonin receptors in the chicken ret-ina, sheep pars tuberalis and Xenopus melanophores. Br. J. Pharmacol (1996) 119:379–387.
   PubMedGoogle Scholar
• LECLERC C, DEPREUX P, LESIEUR D et al: Synthesis and biological activity of conformationally restricted tri-cyclic analogs of the hormone melatonin. BioMed. Chem. Lett. (1996) 6:1071–1076.
   Google Scholar
• MATHE-ALLAINMAT M, GAUDY F, SICSIC S et al.: Synthe-sis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J. Merl. Chem. (1996) 39:3089-3095. The authors emphasised the importance of the relative posi-tions of the naphthalene ring and the amido chain for good recognition by the receptor. They demonstrated the impor-tance of the additional ortho methoxy group in the binding to the receptor site.
   Google Scholar
• JANSEN JM, COPINGA S, GRUPPEN G et al: The high affin-ity melatonin binding site probed with conformation-ally restricted ligands. I. Pharmacophore and minireceptor models. BioMed. Chem. (1996) 4:1321–1332.
   Google Scholar
• GROL CJ, JANSEN JM: The high affinity melatonin bind-ing site probed with conformationally restricted ligands. II. Homology modeling of the receptor. Bio-Med. Chem. (1996) 4:1333–1339.
   Google Scholar
• SICSIC S, SERRAZ I, ANDRIEUX J et al.: Three dimensional quantitative structure-activity relationship of mela-tonin receptor ligands: a comparative molecular field analysis study. J. Merl. Chem. (1997) 40:739-748. The study compared in 3D various melatonin receptorligands with a large molecular diversity and presented a pre-dictive model of their affinity for the melatonin receptor. The steric and electrostatic fields around the binding site were calculated. One of the folded conformers of melatonin can be considered as the active conformer in the binding site of the receptor.
   Google Scholar